Rebecca S Heist1, Lecia V Sequist2, Darrell Borger3, Justin F Gainor2, Ronald S Arellano4, Long P Le5, Dora Dias-Santagata5, Jeffrey W Clark2, Jeffrey A Engelman2, Alice T Shaw2, A John Iafrate5. 1. Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: rheist@partners.org. 2. Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts. 3. Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
INTRODUCTION: MET proto-oncogene, receptor tyrosine kinase gene (MET) exon 14 skipping is a targetable alteration in lung cancer. Treatment with MET proto-oncogene, receptor tyrosine kinase inhibitor can cause dramatic responses in patients whose cancers have MET exon 14 skipping. Little is known, however, about acquired resistance in patients with MET exon 14 skipping. METHODS: Biopsy specimens obtained at baseline and at the time of progression for a patient being treated with crizotinib were compared using targeted next-generation sequencing to assess for mechanisms of resistance. RESULTS: An acquired mutation in the MET kinase domain, D1228N, was found at time of progression on crizotinib in a patient with MET exon 14 skipping. CONCLUSIONS: One potential mechanism of acquired resistance to crizotinib in patients with MET exon 14 skipping is through second-site mutations in the MET gene. Understanding mechanisms of resistance will be important in optimizing therapy in these patients.
INTRODUCTION:MET proto-oncogene, receptor tyrosine kinase gene (MET) exon 14 skipping is a targetable alteration in lung cancer. Treatment with MET proto-oncogene, receptor tyrosine kinase inhibitor can cause dramatic responses in patients whose cancers have MET exon 14 skipping. Little is known, however, about acquired resistance in patients with MET exon 14 skipping. METHODS: Biopsy specimens obtained at baseline and at the time of progression for a patient being treated with crizotinib were compared using targeted next-generation sequencing to assess for mechanisms of resistance. RESULTS: An acquired mutation in the MET kinase domain, D1228N, was found at time of progression on crizotinib in a patient with MET exon 14 skipping. CONCLUSIONS: One potential mechanism of acquired resistance to crizotinib in patients with MET exon 14 skipping is through second-site mutations in the MET gene. Understanding mechanisms of resistance will be important in optimizing therapy in these patients.
Authors: Joon Young Hur; Bo Mi Ku; Joon Ho Shim; Hyun Ae Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Magda Bahcall; Taebo Sim; Cloud P Paweletz; Jyoti D Patel; Ryan S Alden; Yanan Kuang; Adrian G Sacher; Nam Doo Kim; Christine A Lydon; Mark M Awad; Michael T Jaklitsch; Lynette M Sholl; Pasi A Jänne; Geoffrey R Oxnard Journal: Cancer Discov Date: 2016-09-30 Impact factor: 39.397
Authors: Magda Bahcall; Mark M Awad; Lynette M Sholl; Frederick H Wilson; Man Xu; Stephen Wang; Sangeetha Palakurthi; Jihyun Choi; Elena V Ivanova; Giulia C Leonardi; Bryan C Ulrich; Cloud P Paweletz; Paul T Kirschmeier; Masayuki Watanabe; Hideo Baba; Mizuki Nishino; Rebecca J Nagy; Richard B Lanman; Marzia Capelletti; Emily S Chambers; Amanda J Redig; Paul A VanderLaan; Daniel B Costa; Yu Imamura; Pasi A Jänne Journal: Clin Cancer Res Date: 2018-08-02 Impact factor: 12.531
Authors: Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531